Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
CLEO Diagnostics Ltd ( (AU:COV) ) has issued an update.
CLEO Diagnostics Ltd has applied to the ASX for quotation of 8,333,334 new fully paid ordinary shares under its existing issuer code COV, with an issue date of 29 December 2025. The move increases the company’s quoted share capital and may enhance liquidity in its stock, signalling continued capital management activity that could support ongoing development and commercial initiatives in its diagnostics portfolio.
The most recent analyst rating on (AU:COV) stock is a Buy with a A$1.15 price target. To see the full list of analyst forecasts on CLEO Diagnostics Ltd stock, see the AU:COV Stock Forecast page.
More about CLEO Diagnostics Ltd
CLEO Diagnostics Ltd, listed on the ASX under the code COV, operates in the diagnostics and medical technology sector, focusing on the development and commercialisation of diagnostic solutions. The company targets healthcare markets seeking improved tools for early and accurate disease detection.
Average Trading Volume: 255,151
Technical Sentiment Signal: Buy
Current Market Cap: A$80.95M
For an in-depth examination of COV stock, go to TipRanks’ Overview page.